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prevalence and penetrance of BRCA
mutations
Familial susceptibility to breast cancer accounts for 25% of all
breast cancer cases. In familial breast cancer, mutations in the
BRCA1, BRCA2, CHEK2, TP53 and PTEN genes account for
5–10% of breast and ovarian cancer cases overall. The
prevalence of BRCA1 or BRCA2 mutations varies considerably
between ethnic groups and geographical areas. Population-
specific mutations have been described in Iceland, the
Netherlands, Sweden, Norway, Germany, France, Spain,
countries of central and eastern Europe and among Ashkenazi
Jews. The prevalence of BRCA mutation carriers in the general
population is estimated at between 1/800 and 1/1000. BRCA1
and BRCA2 mutation frequencies in breast and ovarian cancer
patients unselected for family history or age at onset are
generally low (<1–7% for BRCA1 and 1–3% for BRCA2).
Higher prevalence is associated with a family history of breast
or ovarian cancer, young age at onset, male breast cancer or
multiple tumors (bilateral breast cancer or breast and ovarian
cancer in the same patient).
Women with an inherited BRCA1 mutation have a lifetime
risk of 65–80% of developing breast cancer and 37–62% of
developing ovarian cancer, while BRCA2 mutation carriers have
a lifetime risk of 45–85% for breast cancer and 11–23% for
ovarian cancer. There is an increased risk of prostate cancer
among BRCA carriers (5–25%) and breast cancer among males
with BRCA2 mutations (6%). Other cancers at increased risk
are pancreatic (up to 2%), stomach, and head and neck.
referral for BRCA testing
Genetic testing criteria may differ between countries based on
mutation prevalence. Widely accepted criteria for referral
include: three or more breast and/or ovarian cancer cases, at
least one aged <50 years; two breast cancer cases aged <40 years;
male breast cancer and early onset female breast cancer; and
breast and ovarian cancer in the same patient [IV, C]. In some
countries, the criterion for testing is that there should be at least
a 10–20% probability of finding a mutation. In all cases, genetic
testing should be performed after genetic counseling and
informed consent.
mutation detection
Most clinically deleterious mutations are protein-truncating
mutations and a small number are missense mutations. Genetic
testing should include complete sequencing of coding regions,
either directly or after a screening method. Since 2–12% of
high-risk families may harbor a large genomic alteration,
specific techniques to detect duplications or deletions of one or
more exons may be indicated [III, B].
risk reduction: non-surgical preventive
options
surveillance
Surveillance of breast cancer in BRCA carriers includes monthly
self-examinations, clinical breast examinations once or twice a year
and yearly mammograms and magnetic resonance imaging (MRI)
of breasts starting at age 25–30 [IIa, B]. There are yet no data
available to determine whether alternating mammogram and MRI
every 6 months or having both once yearly is more effective at
young ages, considering the high rate of interval cancers.
chemoprevention
Adjuvant tamoxifen reduces the risk of contralateral breast
cancer in affected BRCA mutation carriers [III, B], while the
benefit of tamoxifen for primary prevention of breast cancer
has not been demonstrated [III,B].
risk reduction: prophylactic surgical
options
prophylactic bilateral mastectomy
It is the most effective strategy available for risk reduction of
breast cancer in mutation carriers [III, B], although no benefit
in survival has been demonstrated and many women do not
find this strategy acceptable for cosmetic reasons. Contralateral
prophylactic mastectomy is an option to consider in those
BRCA mutation carriers with early breast cancer and unilateral
mastectomy [IV, C].
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prophylactic bilateral salpingo-oophorectomy
It is associated with a risk reduction of breast cancer in
premenopausal BRCA mutation carriers, risk reduction of
ovarian cancer and there is evidence of reduction in overall
mortality. Bilateral salpingo-oophorectomy is recommended
after age 35 and when childbearing decisions are complete
[IIa, B].
Short-term hormonal replacement therapy after bilateral
salpingo-oophorectomy seems not to decrease the overall
benefit of this strategy for breast cancer risk reduction [III, B].
breast cancer treatment
Decisions about surgical treatment of breast cancer in BRCA
mutation carriers should be based on the same parameters as
sporadic cancer, while considering the higher risk of
contralateral breast cancer [III, B].
Standard prognostic features should be used to decide
adjuvant treatment in BRCA mutation carriers with breast
cancer. Ongoing clinical trials in the metastatic setting are
testing the sensitivity to platinum-based chemotherapy of
BRCA tumors and the specific DNA-repair deficiency with the
use of PARP inhibitors.
note
Levels of evidence [I–V] and grades of recommendation [A–D]
as used by the American Society of Clinical Oncology are given
in square brackets. Statements without grading were considered
justified standard clinical practice by the experts and the ESMO
Faculty.
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